Skip to content
Navigate to homepage - Cerba Research

Rare Disease

Our history in specialty testing, your future in cell and gene therapy development.

Facilitating Technology To Accelerate Cell & Gene Therapy

Developing rare disease therapies requires an increased need to access expertise, knowledge, data and insights to bring the right patient to the right treatment at the right time. We facilitate state-of-the art technology, subject matter expertise, specialised logistics and operations to accelerate cell & gene therapy research and development.

Cell & Gene Therapy Highlights

map pin icon

Car T Therapy

Over 20 Clinical trials ongoing in CAR T Therapy

people icon


Assay development

globe icon

Cell Therapies

40+ clinical trials with CAR T, NK cell therapy and engineered donor grafts


  • Uniquely positioned to analyse immune responses in AAV and other gene therapies
  • Validated assays to detect antibodies against viral vectors and target inserts
  • Different technology supporting monitoring of patient safety and efficacy of therapy

Technology & Infrastructure

  • A global processing laboratory infrastructure combined with our specialized logistical and transport services ensures fast analysis of fragile samples
  • White glove logistics – ensuring each sample is tracked at every stage of the process

Our People

  • Scientist to scientist communication – we understand your challenges tailoring solutions to answer your scientific questions
  • Dedicated global project management team, client focused, proactive and transparent communication

Platforms & Laboratories

  • 50+ ELISA based assays to detect antibodies against AAV vectors and target inserts
  • Flow Cytometry – BD FACS Canto & Lyric, Cytek Aurora for MRD, enumeration, immunophenotyping, cell sorting & isolation, tumor microenvironment
  • Genetics – Nucleic acid extraction, NGS for MRD, CAR T enumeration and count, detection, liquid biopsies, gene panels and ctDNA
  • Histopathology – FISH and IHC
  • Molecular Diagnostics – Detecting and quantifying gene/viral genome expression (RCL, VCN) Immune response by monitoring cytokines via MSD platform (37plex MSD)
  • Cell Isolations – PBMC, BMCC, CD138+ with PBMC processing in 25+ countries with 45+ processing labs & growing.
  • Cerba Research is uniquely positioned to analyse immune responses in AAV, CAR-T, NK cell and other personalised gene therapies
Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts to see how we can help you advance your Cell & Gene Therapy Clinical Trial

Contact Us